VistaGen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Meets Estimates

Key Points

• VistaGen Therapeutics reported a quarterly EPS of ($0.47), meeting the consensus estimate, with revenues of $0.24 million exceeding expectations.
• The company's stock has seen an 8.8% increase to $2.97, with a market capitalization of $88.68 million and a PE ratio of -1.67.
• Institutional investors hold 78.39% of VistaGen's stock, indicating strong interest, with a recent stake bought by a hedge fund valued at approximately $25,000.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.47) EPS for the quarter, meeting the consensus estimate of ($0.47), Zacks reports. The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.22 million. VistaGen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 68.45%.

VistaGen Therapeutics Trading Up 8.8%

Shares of VTGN stock traded up $0.24 during trading hours on Friday, hitting $2.97. The company's stock had a trading volume of 442,243 shares, compared to its average volume of 416,901. The company has a 50 day moving average of $2.44 and a 200 day moving average of $2.50. VistaGen Therapeutics has a 12-month low of $1.90 and a 12-month high of $3.79. The stock has a market cap of $88.68 million, a PE ratio of -1.67 and a beta of 0.40.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VistaGen Therapeutics stock. Cubist Systematic Strategies LLC bought a new position in shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,088 shares of the company's stock, valued at approximately $25,000. Institutional investors and hedge funds own 78.39% of the company's stock.

Analyst Ratings Changes

Separately, William Blair reaffirmed an "outperform" rating on shares of VistaGen Therapeutics in a research report on Wednesday, June 18th.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.